# NCT03740165 (NCT03740165)

> Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03740165
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
- Interventions: Pembrolizumab; Placebo for pembrolizumab; Carboplatin; Paclitaxel; Olaparib; Placebo for olaparib; Bevacizumab; Docetaxel
- Enrollment: 1367
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)
- Primary outcome: PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants

## Commentary we found

- YouTube: 10
- Podcasts: 7
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03740165

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03740165", "email": "<work email>"}; the inbox owner confirms by the emailed link.